Although numerous studies have revealed MGMT as a prognostic marker of therapy response [26] and therapy stratification in elderly patients with glioblastoma rests on MGMT [27], it should be noted that there are also studies indicating inconsistencies associated with patients’ outcomes [28], indicating the need for highly standardized methylation-specific PCR in order to avoid biased results. Here, MGMT is linked to glioblastoma.